Enlaza Therapeutics, a pioneering biotechnology company, has successfully raised $100 million in a Series A funding round. This significant financial boost, led by JP Morgan’s Life Sciences Private Capital, marks a substantial move towards advancing their groundbreaking research in cancer treatment. The funding will specifically support the development of permanently binding antibody-drug conjugates (ADCs), a promising new type of cancer therapy.
Founded in late 2022, JP Morgan’s Life Sciences Private Capital aims to support early-stage biotech ventures, and Enlaza Therapeutics is its first public investment. This initiative underscores JP Morgan’s commitment to fostering innovation in the biotech sector.
Enlaza’s research focuses on ADCs that permanently bind to cancer cells, potentially leading to more effective treatments with fewer side effects than traditional therapies. With the new funding, Enlaza plans to initiate the first human trials, an important step in determining the efficacy and safety of their innovative drugs.
The support from JP Morgan not only provides the necessary capital to propel Enlaza’s research forward but also highlights the growing interest and potential in next-Generation therapies in the fight against cancer.
